Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06701214 · ClinicalTrials.gov registry record
The Clonal Hematopoiesis & Inflammation in Vasculature Registry and Biorepository
A clinical trial of Clonal Hematopoiesis, sponsored by Vanderbilt-Ingram Cancer Center.
- Recruiting
- Registry status
- 800
- Enrollment target
- 1
- Study location
NCT06701214 is a study of Clonal Hematopoiesis that is actively recruiting participants, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 800 participants, below the 1,230-participant average among 3 other Clonal Hematopoiesis trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06701214, a study of Clonal Hematopoiesis, is actively recruiting participants, sponsored by Vanderbilt-Ingram Cancer Center.
- RECRUITING
- Registry status
- 800 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will investigate the association between clonal hematopoiesis and other conditions. Clonal hematopoiesis (CH) refers to the mutations in a person's stem cells which commonly affect people as they get older. These mutations have notably been linked to increased risk of certain cancers as well as increased risk of heart disease.
Conditions Studied
Interventions
- OTHER Blood collection
- OTHER Bone marrow collection
- OTHER Saliva collection
Study Locations (1)
Tennessee
- Vanderbilt University/Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2020-10-28 |
| Est. Completion | 2031-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06701214
The ClinicalTrials.gov registry entry for NCT06701214 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,230-participant average among 3 other Clonal Hematopoiesis trials with a reported enrollment target (35% lower). The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Clonal Hematopoiesis appearing as the primary indexed condition, and to 3 interventions - of which Blood collection is the first listed.
NCT06701214 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT06701214 about?
NCT06701214 is a clinical study titled "The Clonal Hematopoiesis & Inflammation in Vasculature Registry and Biorepository". This study will investigate the association between clonal hematopoiesis and other conditions. Clonal hematopoiesis (CH) refers to the mutations in a person's stem cells which commonly affect people as they get older. These mutations have notably been linked to increased risk of certain cancers as w...
What is the current status of trial NCT06701214?
This trial is currently recruiting. The enrollment target is 800 participants. The study started on 2020-10-28. Estimated completion is 2031-11-30.
What conditions does trial NCT06701214 study?
This clinical trial studies the following conditions: Clonal Hematopoiesis.
What interventions are being tested in trial NCT06701214?
The interventions under investigation include: Blood collection (OTHER), Bone marrow collection (OTHER), Saliva collection (OTHER).
Who is sponsoring clinical trial NCT06701214?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06701214 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clonal Hematopoiesis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.